New press release out: HCS Pharma participates in the development of an improved biomimetic liver model on chip for drug discovery

HCS Pharma announces the closure of the “MIMLIVERonChip” project, funded by the French National Research Agency (ANR, project ANR 19 CE19-0020) and coordinated by BMBI Biomechanics and Bioengineering joint research unit (UTC/ CNRS), headed by Dr Cécile Legallais, CNRS research director. This project led to the publication of Taha Messelmani’s Read more…

Feedback of Rania’s internship about the development of primary human hepatocyte model in biochip microfludic system

This is the end of Rania‘s 6-month internship in HCS Pharma about a new liver biochip system. After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular Read more…

New press release out: HCS Pharma, LumiSTAR Biotech & MolDev explore stem cell-derived organoids for drug screening

In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On this occasion, the 3 companies have highlighted their work on hiPSCs (human induced Pluripotent Stem Read more…

Poster – (ECM 2022) Development of innovative hiPSC-based model including an innovative 3D modified hyaluronic acid hydroscaffold for phenotypic screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…

Human liver organoids and disease models, it’s time to use a more realistic ECM

The current hiPSC-derived models are adapted to reproduce diseases of genetic origin in two dimensions and have allowed in recent years to model diseases by using hepatocyte-like-cells (HCL) such as: Alpha1-antitrypsin (A1AT) deficiency (Tafaleng et al., 2015) Familial transthyretin-related amyloidosis (ATTR) (Isono et al., 2014) Glycogen storage deficiency (Satoh et Read more…

A single procedure to generate functional hiPSCs-derived liver organoids -Towards an innovative tool suitable for drug screening

The current hiPSC-derived models are adapted to reproduce diseases of genetic origin. However, the current two-dimensional HLC (hepatocyte like-cells) model has an immature liver phenotype that is more is closer to a perinatal liver. Furthermore, it does not take into account the complexity of the tissues and the extracellular environment Read more…

Poster – A single procedure to generate functional hiPSCs-derived liver organoids -Towards an innovative tool suitable for drug screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of Read more…

Importance of the liver extracellular matrix in the development of NASH/ASH

The extracellular matrix (ECM) is a non-cellular component of tissues and organs. It is mainly composed of structural elements (proteoglycans collagens, elastin) and cell adhesion proteins such as fibronectin and laminins. The ECM forms a complex structure with physical properties (elasticity, tensile and compression strength), which provides physical support for Read more…

Collaboration between “Institut du thorax” and HCS Pharma: improving the management of hypercholesterolemia using a relevant and innovative organoid-based in vitro liver model

Launched in 2016, the adventure is coming to an end after 5 years of work carried out within the RHU CHOPIN (CHOlesterol Personalized INnovation), and with a strong collaboration between HCS Pharma and l’Institut du thorax. This collaborative project of national scope was led by Professor Bertrand Cariou, director of Read more…